Lovastatin: a new “ancient” molecule for hypercholesterolaemia/dyslipidaemia treatment

Gianlorenzo Imperiale, Claudio Marengo

DOI: https://doi.org/10.7175/cmi.v2i2.577


Lovastatin is the first HMGCoA-reductase inhibitor used for the control of hypercholesterolaemia (USA, 1987). In Italy, it’s been authorized for the therapy of hypercholesterolaemia/dyslipidaemia since end 2005. Several studies, conducted both in primary and in secondary cardiovascular prevention, underline the favourable profile in reducing the risk for ischaemic events and their complications. This molecule has the capability to reduce plasmatic atherogenic lipids levels enough to induce clinical benefits. The safety and tolerability of lovastatin are proved even for high dosages, as well as for long term use. Pharmacoeconomic evaluations have shown the value of its choice, in particular for patients who need lipid-lowering treatment but don’t satisfy eligibility criteria for reimbursement by the Italian National Health Service, as outlined by AIFA in 2005.


HMGCoA-reductase inhibitors; Lovastatin; Hypercholesterolaemia; Dyslipidaemia; Cardiovascular disease; Prevention; Economic cost

Full Text



Abstract: 807 views
PDF: 664 views


  • There are currently no refbacks.